INMB FY 2022 Earnings — INmune Bio, Inc. Revenue & Financial Results | Market Cap Arena

INMBINmune Bio, Inc.

$35M

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$374,000+106.6% YoY

Gross Profit

$374,000100.0% margin

Operating Income

-$26M-6938.8% margin

Net Income

-$27M-7299.2% margin

EPS (Diluted)

$-1.52

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$23M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$82M

Total Liabilities

$22M

Stockholders' Equity

$60M

Cash & Equivalents

$52M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$374,000	$181,000	+106.6%
Gross Profit	$374,000	$181,000	+106.6%
Operating Income	-$26M	-$29M	+11.0%
Net Income	-$27M	-$30M	+10.0%